Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2014, Vol. 19 ›› Issue (11): 1312-1316.
Previous Articles Next Articles
ZHU Hong1, XU Zhu-mei2, XIAO Jian2
Received:
2013-12-27
Revised:
2014-10-28
Online:
2014-11-26
Published:
2014-12-09
CLC Number:
ZHU Hong, XU Zhu-mei, XIAO Jian. A new regulatory target of the metabolic syndrome :the farnesoid X receptor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1312-1316.
Add to citation manager EndNote|Ris|BibTeX
URL: https://manu41.magtech.com.cn/Jweb_clyl/EN/
https://manu41.magtech.com.cn/Jweb_clyl/EN/Y2014/V19/I11/1312
[1] | 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中国糖尿病杂志,2012,20(1):S1-S37. |
[2] | Zhu Y, Li F, Guo GL.Tissue-specific Function of Farnesoid X Receptor in Liver and Intestine[J].Pharmacol Res, 2011,63(4):259-265. |
[3] | Miao J, Choi SE, Seok SM, et al.Ligand-dependent regulation of the activity of the orphan nuclear receptor, small heterodimer partner (SHP), in the repression of bile acid biosynthetic CYP7A1 and CYP8B1 genes[J]. Molecular Endocrinol,2011,25(7):1159-1169. |
[4] | Inagaki T, Choi M, Moschetta A, et al.Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis[J]. Cell Metab,2005,2(4):217-225. |
[5] | Claudel T, Staels B, Kuipers F.The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism[J]. Arterioscler Thromb Vasc Biol, 2005,25(10):2020-2030. |
[6] | Insull W Jr.Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review[J]. South Med J, 2006,99(3):257-273. |
[7] | Watanabe M, Houten SM, Wang L, et al.Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c[J]. J Clin Invest, 2004,113(10): 1408-1418. |
[8] | Claudel T, Sturm E, Duez H, et al.Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element[J]. J Clin Invest, 2002,109(7):961-971. |
[9] | Claudel T, Inoue Y, Barbier O, et al.Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression[J]. Gastroenterology, 2003,125(2):544-555. |
[10] | Zhang Y, Yin L, Anderson J, et al.Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia[J]. Biol Chem, 2010,285(5):3035-3043. |
[11] | Fiorucci S, Mencarelli A, Palladino G, et al.Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders[J]. Trends Pharmacol Sci, 2009,30(11):570-580. |
[12] | Zhang Y, Edwards PA.FXR signaling in metabolic disease[J]. FEBS Lett, 2008,582(1):10-18. |
[13] | Cao R, Cronk ZX, Zha W, et al.Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via Gαi-protein-coupled receptors and the AKT pathway[J]. J Lipid Res,2010,51(8): 2234-2244. |
[14] | De Fabiani E, Mitro N, Gilardi F, et al.Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle[J]. J Biol Chem, 2003,278(40):39124-39132. |
[15] | Yamagata K, Daitoku H, Shimamoto Y, et al.Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1[J]. J Biol Chem, 2004,279(22):23158-23165. |
[16] | Stayrook KR, Bramlett KS, Savkur RS, et al.Regulation of carbohydrate metabolism by the farnesoid X receptor[J]. Endocrinology, 2005,146(3):984-991. |
[17] | Thomas C,Gioello A,Noriega L, et al.TRG5-mediated bile acid sensing controls glucose homeostasis[J]. Cell Metabolism ,2009,10(3): 167-177. |
[18] | Zhang Y, Lee FY, Barrera G, et al.Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice[J]. Proc Natl Acad Sci U S A, 2006, 103(4):1006-1011. |
[19] | Duran-Sandoval D, Mautino G, Martin G, et al.Glucose regulates the expression of the farnesoid X receptor in liver[J]. Diabetes,2004,53(4): 890-898. |
[20] | Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice[J]. J Biol Chem,2006 ,281(16):11039-11049. |
[21] | Ma K,Saha P, Chan L, et al.Farnesoid X receptor is essential for normal glucose homeostasis[J]. J Clin Invest,2006,116(4):1102-1109. |
[22] | Renga B, Mencarelli A, Vavassori P, et al.The bile acid sensor FXR regulates insulin transcription and secretion[J]. Biochim Biophys Acta,2010,1802(3):363-372. |
[23] | Düfer M,Hörth K,Wagner R,et al.Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition[J].Diabetes,2012,61(6):1479-1489. |
[24] | Popescu IR, Helleboid-Chapman A, Lucas A, et al.The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity[J]. FEBS Lett, 2010,584(13):2845-2851. |
[25] | Neve B,Fernandez-Zapico ME,Ashkenazi-Katalan V, et al.Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function[J].Proc Natl Acad Sci U S A,2005,102(13):4807-4812. |
[26] | Düfer M, Hörth K, Krippeit-Drews P, et al.The significance of the nuclear farnesoid X receptor (FXR) in β cell function[J].Islets, 2012 ,4(5):333-338. |
[27] | He F, Li J, Mu Y, Kuruba R, et al.Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells[J].Circ Res, 2006 ,98(2):192-199. |
[28] | Cariou B, Staels B.FXR: a promising target for the metabolic syndrome[J] ? Trends Pharmacol Sci, 2007,28(5):236-243. |
[1] | CAI Zuhuan, DENG Taomei, WEI Naijie, ZHU Dan, QIAN Fei, WANG Guangji, ZHANG Jingwei. Silybin ameliorates lipid metabolism disorders in mice with non-alco-holic steatohepatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 241-248. |
[2] | LIU Zhaofeng, LI Ling, NA Shufang, YUE Jiang, YE Qifa. Regulation mechanism of post-translational modification of farnesoid X receptor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1292-1298. |
[3] | DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266. |
[4] | WEI Jifang, YUE Hongmei, LIU Nanyu, SONG Peipei, XIE Yingying, WANG Jiaqi, WEI Yaqian. Research progress on the relationship between thyroid hormone and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 307-313. |
[5] | DUAN Ruixiao, ZHAO Yifan, YE Yongjuan, LIU Min, LI Qiang, ZHOU Yongning. Mechanism of action of bile acid metabolism in regulating inflammatory bowel disease and the research and development of drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1171-1181. |
[6] | GUO Yuting, LI Shanshan, LI Qinglin. Tianma Gouteng Yin protects rotenone-induced PC12 cell damage by inhibiting ferroptosis-lipid metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 8-14. |
[7] | GUO Shengjie, GUAN Xirui, CAO Wenli, LIANG Sicheng, QI Xiaoyi, GE Guangbo, LV Muhan. Research progress on bile acid metabolism mediated by uridine diphosphate glucuronic acid transferase and its endogenous and exogenous influencing factors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 102-107. |
[8] | YANG Hechun, SHI Daohua . Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 836-840. |
[9] | YANG Qian, YU Yunli, ZHANG Quanying. Metabolomics-based analysis of serum BAs in healthy Chinese adults taking acetaminophen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 292-298. |
[10] | LIU Xiaohong, LI Ling, QI Zhenhua, CHEN Binyao, ZHAO Huijia, HAO Zhuowen, YUE Jiang, YE Qifa,WU Jianguo. Farnesoid X receptor is an important target in lipid metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 955-960. |
[11] | SHAO Junjin, LI Ya, LV Lei, WU Kaihua. Effects of dexmedetomidine and hydroxyethyl starch combined with fentanyl on brain glucose and oxygen metabolism in elderly patients with hypertensive cerebral hemorrhage after emergency surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 688-693. |
[12] | WANG Dahui, LV Ying. Protective effects of Modified Qing'e Pill on myocardial tissue in type 2 diabetic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1382-1387. |
[13] | LI Xia, XIAO Di, KOU Hao, ZHANG Li, JI Zhenyu, GUO Yu, WANG Hui. Prenatal ethanol exposure induces dysfunction of glucose metabolism in rats fed by high-fat diet [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 20-26. |
[14] | CHEN Yong-rong, ZHONG Kai-long, HONG Hao. Effects of buqihuoxue particles on glucose and lipid metabolism in streptozotocin-induced type 1 diabetes in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 409-413. |
[15] | CHEN Li, HOU Yong, DU Tian-xi, LI Shao-yin, WANG Guang-ming, ZHU Bang-liu, HUANG De-wu. Effects of Bisphenol A on metabolismof glucose and lipid in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 265-270. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||